Bumetanide attenuates the severity of ASD symptomatology in Tuberous Sclerosis of Bourneville: an open study by Van Andel et al.
In this trial, the authors report that a 3 months open administration of the NKCC1 chloride importer antagonist Bumetanide (0.5-1mg, twice daily) attenuated Autism Spectrum Disorders (ASD) symptomatology in 11 out of 13 patients (8-21 years old). Bumetanide attenuated Irritable Behavior (ABC-I), Social interactions (SRS) and hyperactivity (ABC- hyperactivity subscale), increased the patients’ estimation of … Read more
